GLP-1, plateaus, and 100 lbs lost: what TikTok gets right and wrong

What's this video probably claiming?

With hashtags like #100lbsdown, #plateau, #caloriedeficit, and #fatloss sitting alongside #stairmasterchallenge and #highproteinrecipes, this video is almost certainly Penelope walking viewers through how she lost a significant amount of weight, possibly with GLP-1 medication in the mix, and how she pushed through a plateau. The #leanmuscle tag suggests she's probably talking about preserving or building muscle while losing fat, which is a real concern on GLP-1 drugs. The format looks like a "what I eat in a day" combined with a progress update. These videos tend to carry a few common claims: that GLP-1 medications suppress appetite dramatically, that high-protein eating protects muscle, that cardio like the Stairmaster breaks plateaus, and that a calorie deficit is the core mechanism behind all of it. Some of those claims are well-supported. Others are more complicated than a TikTok allows room for.

What does the science actually show?

On the weight loss side, GLP-1 receptor agonists have strong clinical backing. The STEP 1 trial (Wilding et al., 2021, NEJM) showed semaglutide 2.4 mg weekly produced 14.9% mean body weight reduction over 68 weeks versus 2.4% for placebo. Tirzepatide data from the SURMOUNT-1 trial (Jastreboff et al., 2022, NEJM) pushed that to 20.9% at the highest dose. These are real, meaningful numbers. The plateau problem is also real and documented. As body weight drops, resting metabolic rate decreases and adaptive thermogenesis kicks in (Rosenbaum and Leibel, 2010, Journal of Clinical Investigation). High-protein diets do legitimately help preserve lean mass during a deficit. A meta-analysis by Santesso et al. and work from Layman et al. (2003, Journal of Nutrition) support intakes around 1.2 to 1.6 grams per kilogram of body weight for muscle retention. Cardio contributes to the deficit but does not uniquely break plateaus in any mechanistic way that diet adjustments cannot also achieve.

Where does the social media noise diverge from clinical reality?

Here is where things get messy. Videos like this, even when well-intentioned, tend to compress a medically supervised process into something that looks replicable by anyone watching at home. A few specific divergence points worth flagging. First, muscle retention on GLP-1 drugs is not automatic. A 2023 analysis from the STEP trials noted that approximately 39% of weight lost was lean mass, which is a clinically significant figure that rarely makes it into transformation content. Second, "breaking a plateau" framing usually oversimplifies what is actually happening metabolically. A plateau is often your body reaching a new equilibrium, not a failure of effort. Third, high-protein recipes marketed around GLP-1 use sometimes overclaim their role. Protein matters, but it does not override the hormonal and neurological effects of the medication, nor does it prevent all muscle loss without resistance training. Penelope's personal success is not a clinical protocol, and 84,000 views means a lot of people may be treating it like one.

What should you actually know?

If you are on a GLP-1 medication and trying to lose weight sustainably, the evidence points to a few non-negotiable realities. Resistance training is the most effective intervention for preserving lean mass during significant caloric restriction, more so than protein intake alone (Cava et al., 2017, Nutrients). Protein targets should be individualized by a clinician, not copied from a TikTok meal prep video. Plateaus on GLP-1 drugs sometimes signal that dose titration should be reviewed with a prescriber, not that you need to spend more time on the Stairmaster. And perhaps most importantly, a 100-pound weight loss journey is not a single variable story. Genetics, starting weight, adherence, comorbidities, activity level, and medication dosing all interact in ways that make one person's results genuinely non-transferable to another. Penelope's results are impressive and real. They are also hers.